Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 8/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 7/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22817029 | 0.93 | PARP10 (0.49) | PARP10PARP15PARP2PDK2 | |
| SCHEMBL3717786 | 0.86 | PARP10 (0.46) | PARP10PARP15PARP2SLC6A2SLC6A4 | |
| SCHEMBL2548494 | 0.79 | PARP10 (0.46) | PARP10PARP15PARP2SLC6A2SLC6A4 | |
| SCHEMBL17534137 | 0.79 | PARP10 (0.51) | PARP10PARP15PARP2SLC6A2SLC6A4 | |
| SCHEMBL19874193 | 0.79 | PARP10 (0.51) | PARP10PARP15PARP2SLC6A2SLC6A4 | |
| SCHEMBL22816790 | 0.79 | PARP15 (0.46) | PARP10PARP15PARP2SLC6A2SLC6A4 | |
| SCHEMBL3721180 | 0.79 | PARP10 (0.50) | PARP10PARP15PDK2 | |
| SCHEMBL10989185 | 0.79 | NPC1 (0.36) | KCNH2HSP90AA1 | |
| SCHEMBL18861036 | 0.78 | PARP10 (0.49) | PARP10PARP15PARP2PDK2 | |
| SCHEMBL16902834 | 0.77 | PARP15 (0.59) | PARP10PARP15PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | PARP10 3973/4885PARP15 4007/4885PARP2 3780/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | PARP10 3973/4885PARP15 4007/4885PARP2 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.